following a full submission:
progesterone (Lutigest®) is accepted for use within NHS Scotland.
Indication under review: Luteal support as part of an assisted reproductive technology (ART) treatment program for infertile women.
In women receiving luteal phase support during ART cycles, progesterone (Lutigest®) 100mg vaginal tablets administered three times daily were non-inferior to another progesterone preparation administered vaginally with respect to ongoing pregnancy rates at four to six weeks gestation and live birth rates.
This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of progesterone 100mg vaginal tablets. This advice is contingent on the continuing availability of the patient access scheme in Scotland or a list price that is equivalent or lower.
Download detailed advice172KB (PDF)
Medicine details
- Medicine name:
- progesterone (Lutigest)
- SMC ID:
- 1185/16
- Indication:
- Luteal support as part of an assisted reproductive technology (ART) treatment program for infertile women.
- Pharmaceutical company
- Ferring Pharmaceuticals Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 10 October 2016